Miami-based startup OpenEvidence has reached a $15 billion valuation following a $250 million funding round in September led by Andreessen Horowitz, Blackstone, Thrive Capital, and Sequoia. Founded in 2022 by Daniel Nadler, the company provides an ad-powered AI search engine that helps physicians process patient data, scour peer-reviewed medical journals, and assist in clinical decision-making. The startup processed over 42 million doctor prompts last month and claims to be integrated into major health systems like Mount Sinai, Memorial Sloan Kettering, and NYU Langone.

OpenEvidence booked $100 million in ad commitments for this year at the end of 2025 and projects ad revenues between $400 million and $500 million by late 2026. This growth puts it ahead of traditional clinical software providers such as Wolters Kluwer, which launched an AI version of its subscription-based UpToDate platform in late 2025.

Despite its rapid adoption, the startup faces potential competition as frontier model developers OpenAI and Anthropic push into healthcare. Researchers have also raised concerns regarding the accuracy of AI-generated treatment guidance and the implications of an advertising-driven revenue model in clinical environments.

Why it matters

  • Demonstrates high commercial demand for domain-specific LLM search tools that integrate directly into existing enterprise workflows like electronic health records.

  • Highlights the viability of ad-supported monetization models for specialized B2B and clinical AI applications.

  • Signals growing competitive tension between niche vertical AI startups and broad frontier model providers expanding into specialized sectors.

Source: arstechnica.com